ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To conduct a direct comparison of the effects of Semaglutide and Tirzepatide among adults with obesity but without diabetes. Methods: From January 2024 to February 2026, a total of 183 Chinese adults were enrolled from the obesity clinic at our hospital in a single-center, retrospective observational cohort study. All participants received either once-weekly Semaglutide (1.7mg) or Tirzepatide (5mg) for a duration of three months. The primary outcome was the change in body weight from baseline to month 3. Secondary outcomes included changes in visceral fat mass, appetite, and key metabolic parameters. Body weight, waist circumference, body fat composition, and metabolic parameters were assessed at baseline and at follow-up. Eating behaviors and appetite were evaluated using the Control of Eating Questionnaire (CoEQ) and the Simplified Nutritional Appetite Questionnaire (SNAQ). Results: Both treatments yielded clinically meaningful improvements in body weight, fat mass, and metabolic parameters. Tirzepatide was associated with greater reductions in body weight [-2.87 kg (95% CI, -4.41 to -1.32), p < 0.001)] and higher proportion of patients achieving more than 10% weight loss [21.50% (95% CI, 7.45 to 35.55), p = 0.003]. Moreover, Tirzepatide demonstrated superior efficacy in reducing total fat mass and visceral adiposity, achieving greater total weight loss (TWL%) and excess weight loss (EWL%) percentages, and ameliorating insulin resistance. By contrast, the effects on food cravings and appetite regulation were comparable between the two medications. The overall safety profiles were generally similar between groups. Conclusion: Tirzepatide demonstrates superior efficacy to Semaglutide in obesity management among Chinese adults. Larger-scale and longer-term studies based on real-world clinical practice are warranted to validate and generalize these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.